Targets › HA1
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Oct 2027.
Open in Phaseline: the race on HA1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Fred Hutchinson Cancer Center | CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR (HA-1 T TCR T Cel HA-1 TCR-engineered T cell therapy targeting HA-1 antigen on leukemia cells | HA1 | Phase 1 | Juvenile Myelomonocytic Leukemia | Oct 2027 |
Juvenile Myelomonocytic Leukemia (1)
other (1)
Fred Hutchinson Cancer Center (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.